Filgotinib - Galapagos/Gilead Sciences

Drug Profile

Filgotinib - Galapagos/Gilead Sciences

Alternative Names: Filgotinib hydrochloride; G-146034; G-146034-101; GLPG-0634; GS-6034

Latest Information Update: 17 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; Gilead Sciences
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antirheumatics; Cyclopropanes; Pyridines; Small molecules; Thiamorpholines; Triazoles
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Ankylosing spondylitis; Cutaneous lupus erythematosus; Lupus nephritis; Psoriatic arthritis; Sjogren's syndrome; Uveitis

Most Recent Events

  • 11 Sep 2018 Safety and efficacy data from the phase III FINCH 2 trial in Rheumatoid arthritis released by Gilead Sciences
  • 06 Sep 2018 Efficacy data from a phase II trial in Ankylosing spondylitis released by Gilead Sciences
  • 02 Jul 2018 Galapagos completes a phase II TORTUGA trial for Ankylosing spondylitis in Belgium, Bulgaria, Czech Republic, Estonia, Poland, Spain and Ukraine (PO) (NCT03117270)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top